Cargando…

ISCEV standard pattern reversal VEP development: paediatric reference limits from 649 healthy subjects

PURPOSE: To establish the extent of agreement for ISCEV standard reference pattern reversal VEPs (prVEPs) acquired at three European centres, to determine any effect of sex, and to establish reference intervals from birth to adolescence. METHODS: PrVEPs were recorded from healthy reference infants a...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Dorothy A., Mikó-Baráth, Eszter, Hardy, Sharon E., Jandó, Gábor, Shaw, Martin, Hamilton, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638119/
https://www.ncbi.nlm.nih.gov/pubmed/37938426
http://dx.doi.org/10.1007/s10633-023-09952-9
_version_ 1785146556093038592
author Thompson, Dorothy A.
Mikó-Baráth, Eszter
Hardy, Sharon E.
Jandó, Gábor
Shaw, Martin
Hamilton, Ruth
author_facet Thompson, Dorothy A.
Mikó-Baráth, Eszter
Hardy, Sharon E.
Jandó, Gábor
Shaw, Martin
Hamilton, Ruth
author_sort Thompson, Dorothy A.
collection PubMed
description PURPOSE: To establish the extent of agreement for ISCEV standard reference pattern reversal VEPs (prVEPs) acquired at three European centres, to determine any effect of sex, and to establish reference intervals from birth to adolescence. METHODS: PrVEPs were recorded from healthy reference infants and children, aged 2 weeks to 16 years, from three centres using closely matched but non-identical protocols. Amplitudes and peak times were modelled with orthogonal quadratic and sigmoidal curves, respectively, and two-sided limits, 2.5th and 97.5th centiles, estimated using nonlinear quantile Bayesian regression. Data were compared by centre and by sex using median quantile confidence intervals. The ‘critical age’, i.e. age at which P100 peak time ceased to shorten, was calculated. RESULTS: Data from the three centres were adequately comparable. Sex differences were not clinically meaningful. The pooled data showed rapid drops in P100 peak time which stabilised by 27 and by 34 weeks for large and small check widths, respectively. Post-critical-age reference limits were 87–115 ms and 96–131 ms for large and small check widths, respectively. Amplitudes varied markedly and reference limits for all ages were 5–57 μV and 3.5–56 μV for large and small check widths, respectively. CONCLUSIONS: PrVEP reference data could be combined despite some methodology differences within the tolerances of the ISCEV VEP Standard, supporting the clinical benefit of ISCEV Standards. Comparison with historical data is hampered by lack of minimum reporting guidelines. The reference data presented here could be validated or transformed for use elsewhere. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10633-023-09952-9.
format Online
Article
Text
id pubmed-10638119
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-106381192023-11-14 ISCEV standard pattern reversal VEP development: paediatric reference limits from 649 healthy subjects Thompson, Dorothy A. Mikó-Baráth, Eszter Hardy, Sharon E. Jandó, Gábor Shaw, Martin Hamilton, Ruth Doc Ophthalmol Original Research Article PURPOSE: To establish the extent of agreement for ISCEV standard reference pattern reversal VEPs (prVEPs) acquired at three European centres, to determine any effect of sex, and to establish reference intervals from birth to adolescence. METHODS: PrVEPs were recorded from healthy reference infants and children, aged 2 weeks to 16 years, from three centres using closely matched but non-identical protocols. Amplitudes and peak times were modelled with orthogonal quadratic and sigmoidal curves, respectively, and two-sided limits, 2.5th and 97.5th centiles, estimated using nonlinear quantile Bayesian regression. Data were compared by centre and by sex using median quantile confidence intervals. The ‘critical age’, i.e. age at which P100 peak time ceased to shorten, was calculated. RESULTS: Data from the three centres were adequately comparable. Sex differences were not clinically meaningful. The pooled data showed rapid drops in P100 peak time which stabilised by 27 and by 34 weeks for large and small check widths, respectively. Post-critical-age reference limits were 87–115 ms and 96–131 ms for large and small check widths, respectively. Amplitudes varied markedly and reference limits for all ages were 5–57 μV and 3.5–56 μV for large and small check widths, respectively. CONCLUSIONS: PrVEP reference data could be combined despite some methodology differences within the tolerances of the ISCEV VEP Standard, supporting the clinical benefit of ISCEV Standards. Comparison with historical data is hampered by lack of minimum reporting guidelines. The reference data presented here could be validated or transformed for use elsewhere. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10633-023-09952-9. Springer Berlin Heidelberg 2023-11-08 2023 /pmc/articles/PMC10638119/ /pubmed/37938426 http://dx.doi.org/10.1007/s10633-023-09952-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Research Article
Thompson, Dorothy A.
Mikó-Baráth, Eszter
Hardy, Sharon E.
Jandó, Gábor
Shaw, Martin
Hamilton, Ruth
ISCEV standard pattern reversal VEP development: paediatric reference limits from 649 healthy subjects
title ISCEV standard pattern reversal VEP development: paediatric reference limits from 649 healthy subjects
title_full ISCEV standard pattern reversal VEP development: paediatric reference limits from 649 healthy subjects
title_fullStr ISCEV standard pattern reversal VEP development: paediatric reference limits from 649 healthy subjects
title_full_unstemmed ISCEV standard pattern reversal VEP development: paediatric reference limits from 649 healthy subjects
title_short ISCEV standard pattern reversal VEP development: paediatric reference limits from 649 healthy subjects
title_sort iscev standard pattern reversal vep development: paediatric reference limits from 649 healthy subjects
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638119/
https://www.ncbi.nlm.nih.gov/pubmed/37938426
http://dx.doi.org/10.1007/s10633-023-09952-9
work_keys_str_mv AT thompsondorothya iscevstandardpatternreversalvepdevelopmentpaediatricreferencelimitsfrom649healthysubjects
AT mikobaratheszter iscevstandardpatternreversalvepdevelopmentpaediatricreferencelimitsfrom649healthysubjects
AT hardysharone iscevstandardpatternreversalvepdevelopmentpaediatricreferencelimitsfrom649healthysubjects
AT jandogabor iscevstandardpatternreversalvepdevelopmentpaediatricreferencelimitsfrom649healthysubjects
AT shawmartin iscevstandardpatternreversalvepdevelopmentpaediatricreferencelimitsfrom649healthysubjects
AT hamiltonruth iscevstandardpatternreversalvepdevelopmentpaediatricreferencelimitsfrom649healthysubjects